Have any thoughts about
Seagen Inc?
Write Note

Seagen Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Seagen Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
S
Seagen Inc
F:SGT
Net Issuance of Common Stock
$137m
CAGR 3-Years
11%
CAGR 5-Years
-28%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-10%
CAGR 5-Years
16%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$782m
CAGR 3-Years
11%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$243.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Seagen Inc
Glance View

Market Cap
39.3B EUR
Industry
Biotechnology
Economic Moat
None

Seagen Inc., nestled in the vibrant Pacific Northwest, has carved out a formidable niche in the biotech arena with its relentless focus on oncology advancements. Born in 1997 as Seattle Genetics, this company has developed a reputation for its pioneering work in antibody-drug conjugates (ADCs). These innovative therapies are designed to deliver potent anti-cancer agents directly to tumor cells, minimizing damage to healthy tissues. Its flagship product, Adcetris, targets various Hodgkin’s lymphomas and has been instrumental in redefining treatment paradigms. This high-caliber development is not just a product of cutting-edge science, but of Seagen's strategic approach to partnerships and collaborations with other pharmaceutical giants, amplifying its research and market reach. Revenue for Seagen doesn't merely stem from its internal product pipeline; it also thrives on strategic alliances and licensing agreements. By engaging in collaborations with leading firms like Pfizer and Takeda, Seagen extends its influence beyond its direct sales, earning substantial sums from milestone payments and royalties as partners bring drugs to market. Furthermore, its business model is deeply entwined with a global vision, where navigating regulatory landscapes across different countries not only expands its market share but also its scientific influence. Seagen’s business strategy is a testament to how innovation in drug delivery mechanisms and thoughtful alliances can coalesce into a formidable presence in the biopharmaceutical industry, fueling both growth and a greater mission in the fight against cancer.

SGT Intrinsic Value
143.78 EUR
Overvaluation 31%
Intrinsic Value
Price
S

See Also

What is Seagen Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
137m USD

Based on the financial report for Sep 30, 2023, Seagen Inc's Net Issuance of Common Stock amounts to 137m USD.

What is Seagen Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
13%

Over the last year, the Net Issuance of Common Stock growth was 66%. The average annual Net Issuance of Common Stock growth rates for Seagen Inc have been 11% over the past three years , -28% over the past five years , and 13% over the past ten years .

Back to Top